IP Library Granted Patent US 11,571,466
Granted Patent B2
US 11,571,466 · App. 14/169,628 · Granted Feb 7, 2023

Compositions and methods for treating Gaucher disease

Inventors: Peter Francis Daniel (Natick, MA); Michael W. Heartlein (Boxborough, MA)
Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
A61K38/47A61K9/0019A61K45/06A61P3/00C12N9/2402C12N9/2442C12Y302/01014C12Y302/01045G01N33/6854G01N2333/924G01N2800/044
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,571,466
App. No.
14/169,628
Granted
Feb 7, 2023
Kind
B2
Abstract

Methods and compositions for treating Gaucher disease are described.

Claims (5)

1. A pharmaceutical composition comprising about 2.5 mg/mL of velaglucerase, about 50 mg/mL sucrose, about 12.9 mg/mL sodium citrate dihydrate, about 1.3 mg/mL citric acid monohydrate, and about 0.11 mg/mL polysorbate 20.

2. The composition of claim 1 , wherein the composition is a reconstituted solution.

3. The composition of claim 2 , wherein the composition is reconstituted with sterile water for Injection.

4. A lyophilized pharmaceutical composition comprising velaglucerase, sucrose, sodium citrate dihydrate, citric acid monohydrate, and polysorbate 20, wherein the moisture content of said lyophilized composition is 3% to 5%, and wherein upon reconstitution said lyophilized composition produces a pharmaceutical composition comprising about 2.5 mg/mL of velaglucerase, about 50 mg/mL sucrose, about 12.9 mg/mL sodium citrate dihydrate, about 1.3 mg/mL citric acid monohydrate, and about 0.11 mg/mL polysorbate 20.

5. A method for treating Gaucher disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2021
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055766/0572 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2015
From: DANIEL, PETER F.; HEARTLEIN, MICHAEL W.
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 035901/0249 →
Continuity (7)
Continuation 12845653 · Jul 28, 2010
Provisional Application 61359338 · Jun 28, 2010
Provisional Application 61333372 · May 11, 2010
Provisional Application 61317513 · Mar 25, 2010
Provisional Application 61303044 · Feb 10, 2010
Provisional Application 61229195 · Jul 28, 2009
Related Publication 20140242061A1 · Aug 28, 2014